H.C. Wainwright Rates Palvella Therapeutics as a Buy
H.C. Wainwright initiates coverage on Palvella Therapeutics, citing growth potential of its lead biotech product. Explore its promising sales prospects.
Topic
initiations
A collection of 5 issues
Brookline Rates Medicus Pharma as Buy with $12 Target
Brookline Capital initiates coverage of Medicus Pharma, assigning a Buy rating and targeting $12, highlighting its innovative skin patch technology.
Raymond James Resumes Federal Signal Coverage with Outperform Rating
Raymond James has resumed coverage of Federal Signal (FSS), assigning it an Outperform rating and a $110 price target due to its balanced portfolio. Discover more about its industrial strength.
D. Boral Capital Starts Avita Medical at Buy with $25 Target
D. Boral Capital initiates coverage on Avita Medical (RCEL) with a Buy rating and $25 target, citing promising clinical results in biotechnology.
Raymond James Rates ServiceNow as Outperform with $1,200 Target
Raymond James initiates ServiceNow coverage with an Outperform rating and a $1,200 price target, emphasizing its strong growth potential in the tech sector.